Dr Reddy's Q4 FY26: Navigating R&D Setbacks and US Market Headwinds
Dr Reddys Laboratories Ltd reported a sharp 86% decline in consolidated net profit to Rs 221 crore for the quarter ended March 31, 2026, down from Rs 1,593 crore a year earlier. This significant drop was driven by a combination of one-time impairment charges related to discontinued R&D programs, intense pricing pressure in the crucial US market, and substantial regulatory provisions. Despite these headwinds, the company is executing a strategic pivot toward high-growth areas like semaglutide and biosimilars to rebuild momentum.
The company decided to discontinue certain programs within its Chimeric Antigen Receptor T-cell (CAR-T) therapy portfolio following clinical trial outcomes. While the specific efficacy or safety data from these trials was not publicly disclosed, the decision led to a total impairment charge of Rs 135 crore. This included Rs 129.1 crore towards non-current assets like property, plant, equipment, and intangible assets, alongside Rs 5.9 crore in wind-down costs. Additionally, Dr Reddy's recorded a separate impairment charge of Rs 91.4 crore after discontinuing a late-stage lung cancer study. These R&D write-offs directly contributed to a reported net loss of Rs 135 crore in the global generics segment for the quarter, severely impacting the bottom line. AnnualReports +3
Operational challenges in the US market compounded the impact of these one-time charges. Total revenue from operations fell 11.5% to Rs 7,546 crore, missing analyst estimates of Rs 8,246 crore. This shortfall was primarily attributed to pricing pressure and increasing competition in the US generics market. A major factor was the decline in sales of lenalidomide, a generic version of Bristol-Myers Squibb's cancer drug Revlimid. Following the patent expiry, competition intensified significantly, eroding the sales of a product that had been a strong growth driver for years.
The loss of this high-revenue stream fundamentally altered the company's growth trajectory in North America.
Beyond the R&D impairments, Dr Reddy's profitability was weighed down by significant regulatory provisions. For the full fiscal year 2026, the company recorded a VAT liability provision of Rs 70 crore and a provision of Rs 117 crore related to the implementation of new Labour Codes in India. The Labour Codes provision was retrospective in nature, requiring the re-computation of gratuity and leave encashment obligations for employees. These charges, combined with the impairment losses, created a heavy burden on the company's earnings for the period. For the full year, EBITDA margins narrowed sharply to 22.8% from 28.3% in the previous year, reflecting the cumulative effect of these adverse factors. Transcripts
To counter the decline in lenalidomide and US market pressures, Dr Reddy's is aggressively launching new products. In March 2026, the company launched Obeda, its generic semaglutide injection, in India, becoming the first Indian company to receive DCGI approval for the product. The company plans to expand this launch to Canada, Brazil, Turkey, and over 80 other markets as patents expire. Analysts project the Canadian market alone could generate $80-100 million in revenue for Dr Reddy's in FY27, with the global semaglutide market expected to reach $51.95 billion by 2033. This launch is a cornerstone of the company's strategy to fill the revenue gap left by lenalidomide. Transcripts +2
Dr Reddy's is also investing heavily in biosimilars, consumer health, and innovation to ensure sustainable value creation. The company has launched a denosumab biosimilar in Europe and expects to launch an abatacept biosimilar in July 2027, targeting a $2 billion addressable market. The integration of the Nicotine Replacement Therapy (NRT) business, acquired for Rs 5,276 crore, is 95% complete and is contributing to European revenue growth.
These strategic pillars are designed to diversify revenue away from commoditized generics and improve long-term margins. Transcripts +2
Despite the Q4 profit decline, the company demonstrated resilience in other areas. Branded businesses in India and Europe showed strong growth, aided by favorable currency tailwinds. India revenue grew 19% year-on-year in Q3, while emerging markets grew 32%. To improve margins, Dr Reddy's is implementing cost efficiencies through AI/ML systems for supply chain optimization, which reduced inventory lead times by 20% in 2024, and leveraging automation in manufacturing.
While margin compression remains a challenge due to US pricing pressure, these initiatives aim to stabilize profitability as the new product pipeline ramps up.
